

## Keytruda® (pembrolizumab) – New indication

- On June 29, 2020, the <u>FDA announced</u> the approval of <u>Merck's Keytruda (pembrolizumab)</u>, for the
  first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H)
  or mismatch repair deficient (dMMR) colorectal cancer (CRC).
  - Previously, Keytruda was only approved for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
- Keytruda is also approved for melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, MSI-H or dMMR cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, tumor mutational burden-high cancer, and cutaneous squamous cell carcinoma.
- The approval of Keytruda for the new indication was based on KEYNOTE-177, an open-label, active-controlled trial that enrolled 307 patients with previously untreated unresectable or metastatic MSI-H or dMMR CRC. Patients received Keytruda every 3 weeks or investigator's choice of chemotherapy every 2 weeks until documented disease progression, unacceptable toxicity, or a maximum of 24 months for Keytruda. The main efficacy outcome measures were progression free survival (PFS) and overall survival (OS).
  - The median PFS was 16.5 months for the Keytruda group vs. 8.2 months for the chemotherapy group (Hazard ratio: 0.60; 95% CI: 0.45, 0.80; p = 0.0004).
  - At the time of the PFS analysis, the OS data were not mature (66% of the required number of events for the OS final analysis).
  - In addition, the objective response rate and the duration of response was 44% (95% CI: 35.8, 52.0) and not reached (95% CI: 2.3+. 41.4+) for the Keytruda group vs. 33% (95% CI: 25.8, 41.1) and 10.6 months (95% CI: 2.8, 37.5+) for the chemotherapy group.
- The recommended dose of Keytruda for the treatment of MSI-H or dMMR CRC is 200 mg intravenously every 3 weeks or 400 mg every 6 weeks. Keytruda is administered until disease progression, unacceptable toxicity, or up to 24 months.
- Refer to the Keytruda drug label for dosing for all its other indications.



## optumrx.com

 $OptumRx^{@}\ specializes\ in\ the\ delivery,\ clinical\ management\ and\ affordability\ of\ prescription\ medications\ and\ consumer\ health\ products.$  We are an  $Optum^{@}\ company\ --$  a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.